Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Pamela J Russell"'
Autor:
Yasmin Husaini, Glen P Lockwood, Trung V Nguyen, Vicky Wang-Wei Tsai, Mohammad G Mohammad, Pamela J Russell, David A Brown, Samuel N Breit
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0115189 (2015)
The divergent TGF-β superfamily member, macrophage inhibitory cytokine-1 (MIC-1/GDF15), is overexpressed by most cancers, including prostate cancer (PCa). Whilst its circulating levels are linked to cancer outcome, the role MIC-1/GDF15 plays in canc
Externí odkaz:
https://doaj.org/article/2be7ba62d1c4450bbace7239dda15025
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0125641 (2015)
Externí odkaz:
https://doaj.org/article/23729296c86047ef92d2d165023955a7
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e111029 (2014)
Despite monolayer cultures being widely used for cancer drug development and testing, 2D cultures tend to be hypersensitive to chemotherapy and are relatively poor predictors of whether a drug will provide clinical benefit. Whilst generally more comp
Externí odkaz:
https://doaj.org/article/d5dfec8f8f3440fc8c0568c75d29fab7
Autor:
Yasmin Husaini, Min Ru Qiu, Glen P Lockwood, Xu Wei Luo, Ping Shang, Tamara Kuffner, Vicky Wang-Wei Tsai, Lele Jiang, Pamela J Russell, David A Brown, Samuel N Breit
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43833 (2012)
Macrophage inhibitory cytokine-1 (MIC-1/GDF15), a divergent member of the TGF-β superfamily, is over-expressed by many common cancers including those of the prostate (PCa) and its expression is linked to cancer outcome. We have evaluated the effect
Externí odkaz:
https://doaj.org/article/3d7060ec5f124fee97f3961731fdecb7
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19389 (2011)
BACKGROUND: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastogenesis and osteoclast activity in bone. Here, we used a mixed osteolytic/osteoblastic murine model of bone-metastatic prostate cancer, RM1
Externí odkaz:
https://doaj.org/article/657cfc35f56e45e4b26c8b4f83d18667
Autor:
Jacqui A. McGovern, Nathalie Bock, Abbas Shafiee, Laure C. Martine, Ferdinand Wagner, Jeremy G. Baldwin, Marietta Landgraf, Christoph A. Lahr, Christoph Meinert, Elizabeth D. Williams, Pamela M. Pollock, Jim Denham, Pamela J. Russell, Gail P. Risbridger, Judith A. Clements, Daniela Loessner, Boris M. Holzapfel, Dietmar W. Hutmacher
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
McGovern et al. establish an orthotopic, humanized prostate cancer model to study bone metastasis. The authors demonstrate that a humanized tumor microenvironment (TME) influences the metastatic spread of cancer cells to tissue-engineered bone, highl
Externí odkaz:
https://doaj.org/article/faf5250036f045d891a483661ad13556
Autor:
Kieran F. Scott, Timothy J. Mann, Shadma Fatima, Mila Sajinovic, Anshuli Razdan, Ryung Rae Kim, Adam Cooper, Aflah Roohullah, Katherine J. Bryant, Kasuni K. Gamage, David G. Harman, Fatemeh Vafaee, Garry G. Graham, W. Bret Church, Pamela J. Russell, Qihan Dong, Paul de Souza
Publikováno v:
Molecules, Vol 26, Iss 23, p 7267 (2021)
Phospholipase A2 (PLA2) enzymes were first recognized as an enzyme activity class in 1961. The secreted (sPLA2) enzymes were the first of the five major classes of human PLA2s to be identified and now number nine catalytically-active structurally hom
Externí odkaz:
https://doaj.org/article/eb2e06cdc5944953ae3c4aad2d98fc41
Supplementary Data from Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf917b50ff3276de49c152891f6cccb
https://doi.org/10.1158/1078-0432.22440049.v1
https://doi.org/10.1158/1078-0432.22440049.v1
Purpose: To test the effects of a new combination, cytosine deaminase (CD) + uracil phosphoribosyltransferase (UPRT)–mediated gene-directed enzyme prodrug therapy (GDEPT) with interleukin (IL)-12 and IL-18, on (a) growth of murine prostate and remo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40deafae4837238c9b72b6cd6d2fbb05
https://doi.org/10.1158/1078-0432.c.6517426
https://doi.org/10.1158/1078-0432.c.6517426
Autor:
Pamela J. Russell, Bradley J. Walsh, Brian W.C. Tse, Mei-Chun Yeh, Varinder Jeet, Douglas Campbell, Nicholas L. Fletcher, Marianna Volpert, Chelsea Stewart, Maria E. Lund, Kristofer J. Thurecht, Kamil A. Sokolowski, Colleen C. Nelson, Zachary H. Houston
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)
EJNMMI Research
EJNMMI Research
PurposeChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba38dacb09cb2ec4ef0eabe2e265cd5d
http://link.springer.com/article/10.1186/s13550-020-00637-x
http://link.springer.com/article/10.1186/s13550-020-00637-x